Evidence map›Paper›PMID 34741440›Full record

ArticleCancer medicine2021

Value of screening and follow-up brain MRI scans in patients with metastatic melanoma.

Annemarie C Eggen, Thijs T Wind, Ingeborg Bosma, Miranda C A Kramer, Peter Jan van Laar, Hiska L van der Weide, Geke A P Hospers, Mathilde Jalving

Abstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Automatically tracking brain metastases after stereotactic radiosurgery.Physics and imaging in radiation oncology · 2023
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Annemarie C EggenDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-1412-6419
Thijs T WindDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-3879-3080
Ingeborg BosmaDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Miranda C A KramerDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Peter Jan van LaarDepartment of Radiology, Ziekenhuisgroep Twente, Almelo, and Hengelo, Almelo, The Netherlands.ORCID 0000-0002-3619-2118
Hiska L van der WeideDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0001-6734-2345
Geke A P HospersDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-3047-7892
Mathilde JalvingDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-9142-9050

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel treatments make long-term survival possible for subsets of patients with melanoma brain metastases. Brain magnetic resonance imaging (MRI) may aid in early detection of brain metastases and inform treatment decisions. This study aimed to determine the impact of screening MRI scans in patients with metastatic melanoma and follow-up MRI scans in patients with melanoma brain metastases.

methodsThis retrospective cohort study included patients diagnosed with metastatic melanoma or melanoma brain metastases between June 2015 and January 2018. The impact of screening MRI scans was evaluated in the first 2 years after metastatic melanoma diagnosis. The impact of follow-up MRI scans was examined in the first year after brain metastases diagnosis. The number of MRI scans, scan indications, scan outcomes, and changes in treatment strategy were analyzed.

resultsIn total, 116 patients had no brain metastases at the time of the metastatic melanoma diagnosis. Twenty-eight of these patients (24%) were subsequently diagnosed with brain metastases. Screening MRI scans detected the brain metastases in 11/28 patients (39%), of which 8 were asymptomatic at diagnosis. In the 96 patients with melanoma brain metastases, treatment strategy changed after 75/168 follow-up MRI scans (45%). In patients treated with immune checkpoint inhibitors, the number of treatment changes after follow-up MRI scans was lower when patients had been treated longer. CONCLUSION(S): Screening MRI scans aid in early detection of melanoma brain metastases, and follow-up MRI scans inform treatment strategy. In patients with brain metastases responding to immune checkpoint inhibitors, treatment changes were less frequently observed after follow-up MRI scans. These results can inform the development of brain imaging protocols for patients with immune checkpoint inhibitor sensitive tumors.

Indexed as

AgedBrain NeoplasmsFemaleHumansMagnetic Resonance ImagingMaleMass ScreeningMelanomaNetherlandsRetrospective StudiesSkin Neoplasmsbrain metastasesearly diagnosismelanomaneuroimagingneuro-oncology

Identifiers

PMID34741440
PMCPMC8633235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.